ABVC Biopharma Inc

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company based in Fremont, California, that develops drugs and medical devices to address unmet medical needs in the United States. Its pipeline includes ABV-1501 in Phase II for triple negative breast cancer, ABV-1504 which has completed Phase II for depressive disorders, ABV-1505 in Phase II for adult ADHD, ABV-1702 in Phase II for myelodysplastic syndromes, and ABV-1601 in Phase I/II for depression in cancer patients. The company is also developing ABV-1701 Vitargus in Phase II for retinal detachment or vitreous hemorrhage, ABV-1519 in Phase I/II for non-small cell lung cancer, ABV-2001 an intraocular irrigation solution, ABV-2002 a corneal storage solution, and ABV-1703 in Phase II for metastatic pancreatic cancer. It has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation.